已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers

克拉斯 生物利用度 癌症 口服活性 药理学 医学 结直肠癌 化学 口服 内科学
作者
Fei Xiao,K. Wang,Xinjuan Wang,H. Li,Zhilong Hu,Xiaoming Ren,Wei Huang,Teng Feng,Lili Yao,Jing Lin,Chunlai Li,Zhuanzhuan Zhang,Liufeng Mei,Xiaotian Zhu,Wei-Zhu Zhong,Zhi Xie
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:: OF1-OF14
标识
DOI:10.1158/1535-7163.mct-24-0049
摘要

Abstract KRAS is the most frequently dysregulated oncogene with a high prevalence in non–small cell lung cancer, colorectal cancer, and pancreatic cancer. FDA-approved sotorasib and adagrasib provide breakthrough therapies for patients with cancer with KRASG12C mutation. However, there is still high unmet medical need for new agents targeting broader KRAS-driven tumors. An emerging and promising opportunity is to develop a pan KRAS inhibitor by suppressing the upstream protein of Son of Sevenless 1 (SOS1). SOS1 is a key activator of KRAS and facilitates the conversion of GDP-bound KRAS state to GTP-bound KRAS state. Binding to its catalytic domain, small-molecule SOS1 inhibitor has demonstrated the ability to suppress KRAS activation and cancer cell proliferation. RGT-018, a potent and selective SOS1 inhibitor, was identified with optimal drug-like properties. In vitro, RGT-018 blocked the interaction of KRAS:SOS1 with single-digit nanomoles per liter potency and was highly selective against SOS2. RGT-018 inhibited KRAS signaling and the proliferation of a broad spectrum of KRAS-driven cancer cells as a single agent in vitro. Further enhanced antiproliferation activity was observed when RGT-018 was combined with MEK, KRASG12C, EGFR, or CDK4/6 inhibitors. Oral administration of RGT-018 inhibited tumor growth and suppressed KRAS signaling in tumor xenografts in vivo. Combinations with MEK or KRASG12C inhibitors led to significant tumor regression. Furthermore, RGT-018 overcame the resistance to the approved KRASG12C inhibitors caused by clinically acquired KRAS mutations either as a single agent or in combination. RGT-018 displayed promising pharmacological properties for combination with targeted agents to treat a broader KRAS-driven patient population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HEIKU完成签到,获得积分0
1秒前
科研通AI2S应助lyc45491314采纳,获得10
7秒前
8秒前
颖宝老公完成签到,获得积分10
8秒前
大大大娇搞科研完成签到 ,获得积分10
13秒前
顾矜应助鸭鸭要学习鸭采纳,获得10
14秒前
17秒前
领导范儿应助lyc45491314采纳,获得20
18秒前
28秒前
咸鱼卷完成签到 ,获得积分10
28秒前
31秒前
孤存完成签到 ,获得积分10
32秒前
lyc45491314发布了新的文献求助10
33秒前
橙大炮发布了新的文献求助10
34秒前
ccc发布了新的文献求助10
41秒前
橙大炮完成签到,获得积分10
43秒前
涛哥来科研完成签到 ,获得积分10
44秒前
45秒前
核桃小丸子完成签到 ,获得积分10
48秒前
hucheng完成签到,获得积分10
48秒前
52秒前
xx完成签到 ,获得积分10
52秒前
爆米花应助wing00024采纳,获得10
56秒前
雾蓝发布了新的文献求助20
58秒前
hucheng发布了新的文献求助10
1分钟前
1分钟前
Cathy完成签到,获得积分10
1分钟前
害怕的鱼完成签到 ,获得积分10
1分钟前
EE完成签到 ,获得积分10
1分钟前
今后应助服部平次采纳,获得10
1分钟前
Neo完成签到 ,获得积分10
1分钟前
Shafiq发布了新的文献求助10
1分钟前
神经蛙完成签到,获得积分10
1分钟前
李健的小迷弟应助tttttt采纳,获得10
1分钟前
1分钟前
嗯哼应助风行水上采纳,获得20
1分钟前
服部平次发布了新的文献求助10
1分钟前
Iris完成签到 ,获得积分10
1分钟前
YSY完成签到,获得积分10
1分钟前
1分钟前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3077651
求助须知:如何正确求助?哪些是违规求助? 2730474
关于积分的说明 7512888
捐赠科研通 2378679
什么是DOI,文献DOI怎么找? 1261382
科研通“疑难数据库(出版商)”最低求助积分说明 611496
版权声明 597248